title: Topotecan-induced celluitis-like fixed drug eruption.
authors.forename: N
authors.initials: N
authors.lastname: Senturk
authors.forename: F
authors.initials: F
authors.lastname: Yanik
authors.forename: L
authors.initials: L
authors.lastname: Yildiz
authors.forename: F
authors.initials: F
authors.lastname: Aydin
authors.forename: T
authors.initials: T
authors.lastname: Canturk
authors.forename: A Y
authors.initials: AY
authors.lastname: Turanli
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001707:Biopsy, Needle; D002481:Cellulitis / Q000139:chemically induced* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007262:Infusions, Intravenous; D007868:Leg Dermatoses / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010052:Ovariectomy / Q000379:methods; D018570:Risk Assessment; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D019772:Topotecan